Project Grant K99CA315559
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $144K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute, an office of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $657,443 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA315392). The award funds structural and mechanistic studies of the RAS/RAF MAPKINASE pathway to achieve atomic-resolution understanding of how these proteins recognize and interact with one another and how these interactions...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $235,491 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and career development in cancer research. The award funds investigation into high-count monoclonal B-cell lymphocytosis (HC-MBL) and its relationship to mosaic chromosomal alterations, particularly deletions in chromosome 13q and trisomy 12. The research will examine phenotypic consequences of HC-MBL across two...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $170,394 on July 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support postdoctoral research training in cancer epigenetics. The award funds research examining polycomb repressive complexes and chromatin remodeling in neuroendocrine lineage carcinomas, particularly the transformation of conventional prostate adenocarcinoma into small-cell neuroendocrine prostate cancer. The investigator will conduct...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $606,749 on August 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate novel functions of cell cycle proteins in G1/S phase progression and cancer. The research examines the molecular roles of the cyclin B–CDK1 kinase complex in regulating cell cycle entry and DNA synthesis. Aim 1 uses mouse and human cells to identify the range of molecular functions played by cyclin B–CDK1 during G1/S phase....
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $645,102 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to support research investigating the molecular mechanisms governing WEE1 kinase transition from CDK inhibitor to substrate in cell cycle control. The project addresses how WEE1 kinase shifts between functioning as an active enzyme and as a substrate for phosphorylation at the G2-to-M cell cycle checkpoint. The work focuses on the N-terminal...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $233,478 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to characterize and target acquired resistance to menin-KMT2A inhibitors in acute myeloid leukemia. The award funds research profiling patient samples and patient-derived xenograft models to identify gain-of-function mutations in an oncogenic chromatin complex composed of menin, KMT2A, and PSIP1 proteins that confer resistance to menin...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $230,388 on January 16, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support basic research training in cancer biology and immunotherapy. The award funds research interrogating the role of interferon gamma (IFNG) in promoting metastasis and immune evasion of triple negative breast cancer. The research comprises two aims: elucidating IFNG's role in immune evasion during triple negative breast cancer...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $609,130 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate TRIM28 inhibition as a synthetic lethal strategy for small cell lung cancers with NOTCH2-inactivation. The research will use syngeneic immunocompetent mouse models of small cell lung cancer to test whether TRIM28 inhibition restores anti-tumor immune responses in NOTCH2-mutant tumors. The work builds on prior...